← All trials
NCT04176328
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2019
- Primary completion
- Feb 29, 2020
- Completion date
- Apr 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NeuPharma, Inc.Lead sponsor
- University of VeronaCollaborator
- Sintesi Research SrlCollaborator
- University of VeronaOverall official - principal investigator
- Pari Pharma GmbHCollaborator
- Aptuit Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.